Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
371. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
08-05-2024 |
View |
372. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
08-05-2024 |
View |
373. |
ECCT/24/05/06 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county) |
27-05-2024 |
View |
374. |
ECCT/24/06/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Raymond Scott McClelland Site(s) in Kenya 1. Pwani Research Centre (Mombasa county) |
02-07-2024 |
View |
375. |
ECCT/24/06/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) |
28-07-2024 |
View |
376. |
ECCT/24/07/05 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Bernhards Ogutu Site(s) in Kenya 1. HOMA BAY COUNTY TEACHING AND REFERRAL HOSPITAL SITE (Homa Bay county) |
20-08-2024 |
View |
377. |
ECCT/24/10/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Isaac Tsikhutsu Site(s) in Kenya 1. Kenya Medical Research Institute/Walter Reed Project, Clinical Research Center (Kericho county) |
12-11-2024 |
View |
378. |
ECCT/23/09/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Simon Kariuki Site(s) in Kenya 1. Kenya Medical Research Institute- Centre for Global Health Research (Kisumu county) |
19-12-2023 |
View |
379. |
ECCT/23/11/06 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. AHERO CLINICAL TRIALS UNIT (Kisumu county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
05-02-2024 |
View |
380. |
ECCT/22/10/05 | Agios Study A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease. Mitapivat - AG348-C-020 |
Principal Investigator(s) 1. Videlis N Nduba Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) |
26-02-2023 |
View |